Pinnacle Home Care

Pinnacle Home Care is a full service Medicare Certified and Florida Licensed Home Health Company locally owned and operated by home health professionals who are passionate about delivering exceptional, quality care to the communities that we serve. With over 25 years of executive level home care leadership, you can feel confident that you are partnering with a highly respected organization that has your long-term interests in mind.

Related News

CELL AND GENE THERAPY

2SEVENTY BIO ANNOUNCES EXPANDED COLLABORATION AGREEMENT WITH NOVO NORDISK TO CONTINUE DEVELOPMENT OF IN VIVO GENE EDITING APPROACH

2seventy bio, Inc | January 07, 2022

news image

2seventy bio, Inc. announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A. This agreement builds upon a successful existing multi-year research collaboration between the two companies. Under the terms of this agreement, Novo Nordisk will have the option to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approac...

Read More

YUFAN BIOTECHNOLOGIES AND ABOUND BIO SIGN MULTI-YEAR AGREEMENT TO DEVELOP NEXT GENERATION CAR T-CELL THERAPIES FOR CANCER

Yufan Biotechnologies | September 17, 2020

news image

Exhaustion of T-cells is a key reason why CAR T-cell therapy may fail to control cancer. Recent work led by Xuebin Liao, PhD, Professor of Pharmaceutical Science at Tsinghua University (Si et al., Cancer Cell 2020) shows that HPK1 (hematopoietic progenitor kinase 1) promotes T cell exhaustion via NFkB-Blimp1 activation and that blocking HPK1, either by gene knockout or by small-molecule inhibitors, is an attractive strategy to improve CAR T-cell immunotherapy. These innovative approaches a...

Read More

INDUSTRY OUTLOOK

CUROCELL, BREAKS GROUND ON 'CAR-T MANUFACTURING GMP FACILITY'

Curocell, Inc. | December 24, 2021

news image

Curocell, currently on PhaseⅠCAR-T Therapy clinical trial with CRC01 has recently broken ground for the new CAR-T Center in Dungok Residential & Industrial Area in Daejeon International Science & Business Belt. The GMP Facility for commercial manufacturing CAR-T Cell therapy and R&D Center for further pipeline development are constituting the 17,325 square-meter site of CAR-T Center. By the first half of 2023, construction is expected to be completed and...

Read More

DIAGNOSTICS

ONCODE INSTITUTE AND ARGOBIO LAUNCH LAIGO BIO, A TARGETED PROTEIN DEGRADATION BIOTECH WITH PROGRAMS IN ONCOLOGY AND NEUROLOGICAL DISORDERS

ArgoBio and Oncode Institute | February 08, 2022

news image

ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice, researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation. The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR. The SureTACsR technology platform is a novel approach in membrane protein degradation, applicable to a broad scope of ...

Read More
news image

CELL AND GENE THERAPY

2SEVENTY BIO ANNOUNCES EXPANDED COLLABORATION AGREEMENT WITH NOVO NORDISK TO CONTINUE DEVELOPMENT OF IN VIVO GENE EDITING APPROACH

2seventy bio, Inc | January 07, 2022

2seventy bio, Inc. announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A. This agreement builds upon a successful existing multi-year research collaboration between the two companies. Under the terms of this agreement, Novo Nordisk will have the option to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approac...

Read More
news image

YUFAN BIOTECHNOLOGIES AND ABOUND BIO SIGN MULTI-YEAR AGREEMENT TO DEVELOP NEXT GENERATION CAR T-CELL THERAPIES FOR CANCER

Yufan Biotechnologies | September 17, 2020

Exhaustion of T-cells is a key reason why CAR T-cell therapy may fail to control cancer. Recent work led by Xuebin Liao, PhD, Professor of Pharmaceutical Science at Tsinghua University (Si et al., Cancer Cell 2020) shows that HPK1 (hematopoietic progenitor kinase 1) promotes T cell exhaustion via NFkB-Blimp1 activation and that blocking HPK1, either by gene knockout or by small-molecule inhibitors, is an attractive strategy to improve CAR T-cell immunotherapy. These innovative approaches a...

Read More
news image

INDUSTRY OUTLOOK

CUROCELL, BREAKS GROUND ON 'CAR-T MANUFACTURING GMP FACILITY'

Curocell, Inc. | December 24, 2021

Curocell, currently on PhaseⅠCAR-T Therapy clinical trial with CRC01 has recently broken ground for the new CAR-T Center in Dungok Residential & Industrial Area in Daejeon International Science & Business Belt. The GMP Facility for commercial manufacturing CAR-T Cell therapy and R&D Center for further pipeline development are constituting the 17,325 square-meter site of CAR-T Center. By the first half of 2023, construction is expected to be completed and...

Read More
news image

DIAGNOSTICS

ONCODE INSTITUTE AND ARGOBIO LAUNCH LAIGO BIO, A TARGETED PROTEIN DEGRADATION BIOTECH WITH PROGRAMS IN ONCOLOGY AND NEUROLOGICAL DISORDERS

ArgoBio and Oncode Institute | February 08, 2022

ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice, researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation. The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR. The SureTACsR technology platform is a novel approach in membrane protein degradation, applicable to a broad scope of ...

Read More